Date:8/9/2012

batch failures, variability in batch yields, required maintenance or other causes, we may not be able to satisfy patient demand or build safety stock. Additionally, the ability to increase the number of shifts to produce Cinryze at Sanquin is subject to labor relations at Sanquin, including but not limited to labor availability and the time necessary to train such additional labor.  Our inability to obtain adequate product supplies to satisfy our patient demand may create opportunities for our competitors and we will suffer a loss of potential future revenues. These factors, and other factors, including, but not limited to those described in ViroPharma's Annual report on Form 10-K for the year ended December 31, 2011 and our subsequent Quarterly Reports on Form 10-Q, could cause future results to differ materially from the expectations expressed in this press release. The forward-looking statements contained in this press release may become outdated over time. ViroPharma does not assume any responsibility for updating any forward-looking statements. VIROPHARMA INCORPORATEDSelected Financial Information(unaudited)(unaudited)Consolidated Statements of Operations:Three months endedSix months ended(in thousands, except per share data)

June 30,June 30,2012201120122011Revenue:Net product sales

$
94,639$   128,808$
230,439$   255,843Costs and Expenses:Cost of sales (excluding amortization of product rights)

24,72121,30956,79940,179Research and development

16,62120,41732,02030,843Selling, general and administrative

40,88332,09079,04660,376Intangible amortization

8,7877,15617,61416,053Other operating expenses

8585,5282,0546,026Total costs and expenses

91,87086,500187,533153,477Operating income 

2,76942,30842,906102,366Other Income (Expense):Interest income

142189278394Interest expense

(3,518)(3,066)(6,965)(6,023)Other (expense) income, net

(4,
'/>"/>

SOURCE ViroPharma Incorporated Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12
Related medicine technology :

1. ViroPharma To Release 2012 Second Quarter Financial Results On August 9, 2012
2. Berger & Montague, P.C. Reminds Viropharma Shareholders That The Deadline To Petition The Court To Act As Lead Plaintiff Is July 23, 2012
3. ViroPharma To Participate In The JMP Securities Healthcare Conference
4. Faruqi & Faruqi, LLP Announces Investigation of ViroPharma Incorporated
5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
6. Accuray Incorporated to Speak at Wells Fargo Healthcare Conference
7. Accuray Incorporated to Speak at Jefferies Global Healthcare Conference
8. Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease
9. Insmed Incorporated Announces Lifting of Clinical Hold by U.S. Food and Drug Administration on ARIKACE® in Cystic Fibrosis Patients With Pseudomonas Lung Infections
10. The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Gen-Probe Incorporated in Connection with the Sale of the Company to Hologic, Inc.
11. GenVec Reports Second Quarter 2012 Financial Results